This has important clinical implications because it suggests that allocation of add-on therapies to lower lipid levels, such as proprotein convertase subtilisin/kexin type 9 inhibitors, in patients with high LDL-C levels could be informed by severity of coronary artery disease. The gene discussed is PCSK9; the disease is coronary artery disorder.